Literature DB >> 19496189

Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice.

Jing Li1, Yun-Feng Piao, Zheng Jiang, Li Chen, Hai-Bo Sun.   

Abstract

AIM: To explore the effect of silencing of signal transducer and activator of transcription 3 (STAT3) expression by RNA interference (RNAi) on growth of human hepatocellular carcinoma (HCC) in tumor-bearing nude mice in vivo.
METHODS: To construct the recombinant plasmid of pSilencer 3.0-H1-STAT3-siRNA-GFP (pSH1-siRNA-STAT3) and establish the tumor-bearing nude mouse model of the HCC cell line SMMC7721, we used intratumoral injection together with electroblotting to transfect the recombinant plasmid pSH1-siRNA-STAT3 into the transplanted tumor. The weight of the nude mice and tumor volumes were recorded. STAT3 gene transcription was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). Level of protein expression and location of STAT3 were determined by Western blotting and immunohistochemical staining. STAT3-related genes such as survivin, c-myc, VEGF, p53 and caspase3 mRNA and protein expression were detected in tumor tissues at the same time. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was used to detect apoptosis of tumor cells.
RESULTS: The weight of the treated nude mice increased, and the tumor volume decreased markedly compared with those of the mock-treated and negative control groups (P < 0.01). The results of RT-PCR and Western blotting showed that mRNA and protein levels of STAT3 declined markedly in the treated group. The change in STAT3-related gene expression in tumor tissues at the mRNA and protein level also varied, the expression of survivin, VEGF and c-myc were obviously reduced, and expression of p53 and caspase3 increased (P < 0.01). Most of the tumor tissue cells in the treated group developed apoptosis that was detected by TUNEL assay.
CONCLUSION: Silencing of STAT3 expression by RNAi significantly inhibits expression of STAT3 mRNA and protein, and suppresses growth of human HCC in tumor-bearing nude mice. The mechanism may be related to down-regulation of survivin, VEGF and c-myc and up-regulation of p53 and caspase3 expression. Accordingly, the STAT3 gene may act as an important and effective target in gene therapy of HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496189      PMCID: PMC2691490          DOI: 10.3748/wjg.15.2602

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

2.  Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.

Authors:  Lifang Gao; Ling Zhang; Jiadi Hu; Feng Li; Yueting Shao; Dan Zhao; Dhananjaya V Kalvakolanu; Dennis J Kopecko; Xuejian Zhao; De-Qi Xu
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

Review 3.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

4.  Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.

Authors:  Hajime Isomoto; Shogo Kobayashi; Nathan W Werneburg; Steve F Bronk; Maria Eugenia Guicciardi; David A Frank; Gregory J Gores
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

5.  G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.

Authors:  Naijie Jing; Yidong Li; Weijun Xiong; Wei Sha; Ling Jing; David J Tweardy
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

6.  Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.

Authors:  Li-Bo Chen; Jun-Yao Xu; Zhen Yang; Guo-Bin Wang
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

7.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

Authors:  Tianhong Wang; Guilian Niu; Marcin Kortylewski; Lyudmila Burdelya; Kenneth Shain; Shumin Zhang; Raka Bhattacharya; Dmitry Gabrilovich; Richard Heller; Domenico Coppola; William Dalton; Richard Jove; Drew Pardoll; Hua Yu
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  Antitumor electrochemotherapy: new advances in the clinical protocol.

Authors:  C Domenge; S Orlowski; B Luboinski; T De Baere; G Schwaab; J Belehradek; L M Mir
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

9.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity.

Authors:  James Turkson; Joon S Kim; Shumin Zhang; Jing Yuan; Mei Huang; Matthew Glenn; Eric Haura; Said Sebti; Andrew D Hamilton; Richard Jove
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

10.  STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.

Authors:  Taro Kijima; Hideo Niwa; Richard A Steinman; Stephanie D Drenning; William E Gooding; Abbey L Wentzel; Sichuan Xi; Jennifer Rubin Grandis
Journal:  Cell Growth Differ       Date:  2002-08
View more
  9 in total

1.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

2.  Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.

Authors:  Ondrej Uher; Veronika Caisova; Lucie Padoukova; Karolina Kvardova; Kamila Masakova; Radka Lencova; Andrea Frejlachova; Marketa Skalickova; Anna Venhauerova; Adela Chlastakova; Per Hansen; Jindrich Chmelar; Jan Kopecky; Zhengping Zhuang; Karel Pacak; Jan Zenka
Journal:  Cancer Immunol Immunother       Date:  2021-04-15       Impact factor: 6.968

3.  Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines.

Authors:  Wolfgang Glienke; Eva Hausmann; Lothar Bergmann
Journal:  Tumour Biol       Date:  2010-12-21

Review 4.  STAT3 signaling in pulmonary arterial hypertension.

Authors:  Roxane Paulin; Jolyane Meloche; Sébastien Bonnet
Journal:  JAKSTAT       Date:  2012-10-01

5.  STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice.

Authors:  Hai dong Li; Chen Huang; Ke jian Huang; Wei dong Wu; Tao Jiang; Jun Cao; Zhen zhong Feng; Zheng jun Qiu
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

6.  The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model.

Authors:  Tereza Janotová; Marie Jalovecká; Marie Auerová; Ivana Švecová; Pavlína Bruzlová; Veronika Maierová; Zuzana Kumžáková; Štěpánka Cunátová; Zuzana Vlčková; Veronika Caisová; Petra Rozsypalová; Katarína Lukáčová; Nikol Vácová; Markéta Wachtlová; Jiří Salát; Jaroslava Lieskovská; Jan Kopecký; Jan Ženka
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

7.  Off-target effects of plasmid-transcribed shRNAs on NFκB signaling pathway and cell survival of human melanoma cells.

Authors:  Kavita Ramji; Dorota Weronika Kulesza; Salem Chouaib; Bozena Kaminska
Journal:  Mol Biol Rep       Date:  2013-10-30       Impact factor: 2.316

8.  Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.

Authors:  Veronika Caisová; Andra Vieru; Zuzana Kumžáková; Simona Glaserová; Hana Husníková; Nikol Vácová; Gabriela Krejčová; Lucie Paďouková; Ivana Jochmanová; Katherine I Wolf; Jindřich Chmelař; Jan Kopecký; Jan Ženka
Journal:  BMC Cancer       Date:  2016-12-07       Impact factor: 4.430

Review 9.  Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review.

Authors:  Nathália Alves Araújo de Almeida; Camilla Rodrigues de Almeida Ribeiro; Jéssica Vasques Raposo; Vanessa Salete de Paula
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.